NCT06958588 Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis
| NCT ID | NCT06958588 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Science Valley Research Institute |
| Condition | Venous Thromboembolism (VTE) |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-05-25 |
| Primary Completion | 2025-12-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 50 participants in total. It began in 2025-05-25 with a primary completion date of 2025-12-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Venous thromboembolism (VTE) is frequent in patients in the intensive care unit (ICU). Pharmacologic prophylaxis is sometimes contraindicated, and mechanical prophylaxis is used. The primary objective of the study is to compare Pulsed Electromagnetic Field Therapy (PEMF) with conventional mechanical prophylaxis for the prevention of VTE in patients in the ICU.
Eligibility Criteria
Inclusion Criteria: 1. Patients \> 18 years old in ICU 2. PADUA score\> 4 (medical patients) and/or Caprini score\> 3 (surgical patients) 3. Contraindication to pharmacological prophylaxis or indication to combined (pharmacological and mechanical VTE prophylaxis) Exclusion Criteria: 1. Patients \< 18 years old in ICU 2. Unable to use mechanical prophylaxis due to trauma, burns, fracture, or problems in inferior members that prevent the use of mechanical prophylaxis 3. Life expectations less than 24 hours
Contact & Investigator
Eduardo Ramacciotti, MD, Ph.D.
STUDY CHAIR
Science Valley Research Organization
Frequently Asked Questions
Who can join the NCT06958588 clinical trial?
This trial is open to participants of all sexes, studying Venous Thromboembolism (VTE). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06958588 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06958588 currently recruiting?
Yes, NCT06958588 is actively recruiting participants. Contact the research team at edu.sad@uol.com.br for enrollment information.
Where is the NCT06958588 trial being conducted?
This trial is being conducted at Belo Horizonte, Brazil.
Who is sponsoring the NCT06958588 clinical trial?
NCT06958588 is sponsored by Science Valley Research Institute. The principal investigator is Eduardo Ramacciotti, MD, Ph.D. at Science Valley Research Organization. The trial plans to enroll 50 participants.